<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/293BE4EA-B28B-4D89-A4D0-D5F6349AC6C4"><gtr:id>293BE4EA-B28B-4D89-A4D0-D5F6349AC6C4</gtr:id><gtr:name>Randox Laboratories</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8B397931-E408-4411-9815-5BECA5DCEFFA"><gtr:id>8B397931-E408-4411-9815-5BECA5DCEFFA</gtr:id><gtr:name>LGC Limited</gtr:name><gtr:address><gtr:line1>Queens Road</gtr:line1><gtr:postCode>TW11 0LY</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/961756BF-E31F-4A13-836F-0A09BA02385C"><gtr:id>961756BF-E31F-4A13-836F-0A09BA02385C</gtr:id><gtr:name>University of Exeter</gtr:name><gtr:address><gtr:line1>University of Exeter</gtr:line1><gtr:line2>Clydesdale House</gtr:line2><gtr:line3>Clydesdale Road</gtr:line3><gtr:line4>Exeter</gtr:line4><gtr:postCode>EX4 4QX</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/961756BF-E31F-4A13-836F-0A09BA02385C"><gtr:id>961756BF-E31F-4A13-836F-0A09BA02385C</gtr:id><gtr:name>University of Exeter</gtr:name><gtr:address><gtr:line1>University of Exeter</gtr:line1><gtr:line2>Clydesdale House</gtr:line2><gtr:line3>Clydesdale Road</gtr:line3><gtr:line4>Exeter</gtr:line4><gtr:postCode>EX4 4QX</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/293BE4EA-B28B-4D89-A4D0-D5F6349AC6C4"><gtr:id>293BE4EA-B28B-4D89-A4D0-D5F6349AC6C4</gtr:id><gtr:name>Randox Laboratories</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8B397931-E408-4411-9815-5BECA5DCEFFA"><gtr:id>8B397931-E408-4411-9815-5BECA5DCEFFA</gtr:id><gtr:name>LGC Limited</gtr:name><gtr:address><gtr:line1>Queens Road</gtr:line1><gtr:postCode>TW11 0LY</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E85CC15B-5865-4815-84A9-CBD70BCB93E8"><gtr:id>E85CC15B-5865-4815-84A9-CBD70BCB93E8</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Randall</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3BEBE731-2294-4B5D-9EF2-27D93975C3B3"><gtr:id>3BEBE731-2294-4B5D-9EF2-27D93975C3B3</gtr:id><gtr:firstName>Angela</gtr:firstName><gtr:surname>Shore</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1D34C471-9DAD-4614-A6E0-3E2F6AFDDB2A"><gtr:id>1D34C471-9DAD-4614-A6E0-3E2F6AFDDB2A</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:otherNames>Andrew</gtr:otherNames><gtr:surname>Goodwin</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/63454C57-257F-4FAE-8D1D-410381F0B810"><gtr:id>63454C57-257F-4FAE-8D1D-410381F0B810</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Hattersley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_15047"><gtr:id>D28D1F5A-EBBB-4F22-AB79-E840D00A0508</gtr:id><gtr:title>Precision Medicine Exeter Innovation Platform (PMEI Platform): Proof of Concept Funds</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_15047</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2018-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>200000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>LGC Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>LGC - M Weedon</gtr:description><gtr:id>BFB91847-94AE-443F-A5F7-DC26526116DE</gtr:id><gtr:impact>Reagents for genotyping have been provided at cost price, providing an in-kind contribution equivalent to &amp;pound;10,959.</gtr:impact><gtr:outcomeId>58c13184632e46.61266959-1</gtr:outcomeId><gtr:partnerContribution>LGC has agreed to provide preferential pricing and a marketing launch to assist with awareness</gtr:partnerContribution><gtr:piContribution>The research team will be working on a collaboration with LGC genomics to develop a simple single nucleotide polymorphism (SNP) based test to help classify patients with diabetes by subtype of disease</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Randox Laboratories</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Randox - M Weedon</gtr:description><gtr:id>F04716CA-6352-43FA-A8B7-C8AE27025470</gtr:id><gtr:impact>Outcomes are pending; the plan is to have a genotyping product which can be situated in clinical chemistry so that clinicians can get a genetic test at diagnosis of diabetes to ensure accurate diagnosis. The test will incorporate genetic, clinical and any biomarker data (e.g. antibodies or c-peptide) to provide an accurate probability of diabetes subtype. The potential impact of this product will be on patients who will get the correct diagnosis of diabetes. Given that 15% of young (20-50yr) adults have their diabetes misdiagnosed this is a lot of individuals who are, for example, taking insulin needlessly. This will also impact the NHS finances by ensuring only people that require insulin are on insulin and that the correct treatment is provided so that diabetes is better controlled and diabetes-associated diseases are less common and cost the NHS less.</gtr:impact><gtr:outcomeId>58c2de8c182733.92024600-1</gtr:outcomeId><gtr:partnerContribution>Randox have developed a version of their array technology for the genetic variants that are required for performing the Type 1 diabetes genetic risk score. Randox have genotyped samples provided by and error rates were &amp;lt; 0.05%. They are working on improving the accuracy of the test further.</gtr:partnerContribution><gtr:piContribution>Preliminary meetings with Randox have taken place to outline a potential project and collaboration. UoE have provided Randox with samples as a test of the assay validity. The aim is to provide Randox with the statistical model which will incorporate genetic information with clinical and other biomarker information to give a highly predictive Type 1 diabetes probability.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>20166</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Exeter, IIB Open Innovation funding platform: AWARDED to J TERRY</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Higher Education Funding Council for England (HEFCE)</gtr:fundingOrg><gtr:id>E8DC3337-E9AA-4305-B0D3-97BE17914292</gtr:id><gtr:outcomeId>58c1288d2444a3.55474441</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Assessing Susceptibility to Epilepsy and Epileptic Seizures A method and system adapted to assist with assessing susceptibility to epilepsy and/or epileptic seizures in a patient receives (202) patient brain data and generates (204) a network model from the received patient brain data. The system further generates (206) synthetic brain activity data in at least some of the nodes of the network model and computes (208) seizure frequency from the synthetic brain activity data by monitoring transitions from non-seizure states to seizures states in at least some of the nodes over time. The system further includes a device (104, 110) configured to use the seizure frequency to compute (210) a likelihood of susceptibility to epilepsy and/or epileptic seizures in the patient, and a device (104, 110) configured to compare (212) the computed likelihood with another likelihood of susceptibility to epilepsy and/or epileptic seizures in order to assess whether the likelihood has increased or decreased. Fig. 2</gtr:description><gtr:grantRef>MC_PC_15047</gtr:grantRef><gtr:id>073E2D58-1EC3-42DC-A7BB-4B9E2222D386</gtr:id><gtr:impact>We are in the early stages of forming a spin-out company, in collaboration with the King's College IP and Licencing team, following the results of our health economic assessment quantifying the economic potential of our technology.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58c13eaa739db6.43348339</gtr:outcomeId><gtr:patentId>WO2013182848</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>ASSESSING SUSCEPTIBILITY TO EPILEPSY AND EPILEPTIC SEIZURES</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention relates to a compound comprising a mitochondrial targeting group linked to group capable of releasing hydrogen sulfide, or a pharmaceutically acceptable salt thereof, for use in the treatment of the human or animal body by surgery or therapy. The invention also relates to the use of the compound in the treatment of a plant, and to certain forms of the compound.</gtr:description><gtr:grantRef>MC_PC_15047</gtr:grantRef><gtr:id>CCA2CE13-FD1E-4169-9FB3-744201405287</gtr:id><gtr:impact>None at this point</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58c13e4b1628e2.69500347</gtr:outcomeId><gtr:patentId>WO2013045951</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>HYDROGEN SULFIDE RELEASING COMPOUNDS AND THEIR USE</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5EB80ABB-4211-4779-A9DC-409CCA0FDAAB</gtr:id><gtr:title>Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank</gtr:title><gtr:parentPublicationTitle>The Lancet Diabetes &amp; Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c31b0a7109bf3aa4318f1c0ba90e0f4d"><gtr:id>c31b0a7109bf3aa4318f1c0ba90e0f4d</gtr:id><gtr:otherNames>Thomas N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5aa138154bf337.16723637</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56C42E1A-05D7-44AB-81B2-81D75065EF17</gtr:id><gtr:title>An Amish founder mutation disrupts a PI(3)P-WHAMM-Arp2/3 complex-driven autophagosomal remodeling pathway.</gtr:title><gtr:parentPublicationTitle>Molecular biology of the cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3e1609de5cb7b779f765cfea346f182"><gtr:id>d3e1609de5cb7b779f765cfea346f182</gtr:id><gtr:otherNames>Mathiowetz AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1059-1524</gtr:issn><gtr:outcomeId>5aa13d34766051.39578401</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B71A7A0B-C2C6-4675-B863-A4CDEE4D56B2</gtr:id><gtr:title>AP39, a mitochondria-targeting hydrogen sulfide (HS) donor, protects against myocardial reperfusion injury independently of salvage kinase signalling.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44f524f70747076073607d8d7c3676a1"><gtr:id>44f524f70747076073607d8d7c3676a1</gtr:id><gtr:otherNames>Karwi QG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5a9ffaa15d0a57.83156493</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_15047</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>